Zylox-Tonbridge Sets Governance Framework for Remuneration Committee

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has issued an update.

Zylox-Tonbridge Medical Technology Co., Ltd. has formalized the terms of reference for its Remuneration Committee, setting requirements for at least three members, a majority of whom must be independent non-executive directors. The committee chair must also be an independent non-executive director, and members are required to disclose personal financial interests or potential conflicts and abstain from related decisions.

The document specifies that the committee will meet at least once a year, operate under the company’s Articles of Association, and pass resolutions by majority vote, with a quorum of at least two-thirds of members including one independent non-executive director. These measures are designed to strengthen oversight of director and senior management pay, enhance transparency in remuneration decisions, and align the company’s governance practices with market expectations and regulatory norms.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. operates in the medical technology sector, developing and manufacturing healthcare devices and solutions. The company is governed by a board of directors that includes independent non-executive directors, reflecting a structure aligned with corporate governance standards in its industry.

Average Trading Volume: 700,433

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.31B

For detailed information about 2190 stock, go to TipRanks’ Stock Analysis page.